results

interview Introduction In our latest interview, we had the opportunity to speak with Jan-Willem Boiten, the leader of Work Package 2 (WP2) in the Immune-Image project. Jan-Willem shared exciting insights into the progress and future plans of his work package,...

PAPER Introduction Immunotherapy targeted to immune checkpoint inhibitors, such as the program cell death receptor (PD-1) and its ligand (PD-L1), has revolutionized cancer treatment. However, it is now well-known that PD-1/PD-L1 immunotherapy response is inconsistent...

ABSTRACT Objective Improving patient selection and development of biological therapies such as vedolizumab in IBD requires a thorough understanding of the mechanism of action and target binding, thereby providing individualised treatment strategies. We aimed to...

Abstract Background Distribution of mAbs into tumour tissue may occur via different processes contributing differently to the 89Zr-mAb uptake on PET. Target-specific binding in tumours is of main interest; however, non-specific irreversible uptake may also be present,...

Introduction 89Zr-immuno-PET (positron emission tomography with zirconium-89-labeled monoclonal antibodies ([89Zr]Zr-mAbs)) can be used to study the biodistribution of mAbs targeting the immune system. The measured uptake consists of target-specific and non-specific...

ABSTRACT Background PET scans using zirconium-89 labelled monoclonal antibodies (89Zr-mAbs), known as 89Zr-immuno-PET, are made to measure uptake in tumour and organ tissue. Uptake is related to the supply of 89Zr-mAbs in the blood. Measuring activity concentrations...

Introduction The human immune system contains a complex network of cells and organs, each with their own unique functions. Within this intricate tapestry, macrophages play an indispensable role займ без проверки кредитной истории. These immune cells are involved in a...